Given its role in shaping the TME and influencing immune cell infiltration, IGF2BP2 may serve as a potential therapeutic target for enhancing the efficacy of immunotherapy in bladder cancer. The gene discussed is IGF2BP2; the disease is urinary bladder cancer.